#FDA approval

Alzheimer’s advocates laud the approval of Aduhelm, but experts raise questions about its effectiveness and cost.

Here are the latest new cancer drugs approved by the Food and Drug Administration.

The Food and Drug Administration created its accelerated approval program to enable more rapid approval of therapies for serious conditions.

The agent is approved for use in men suspected of having either metastatic or recurrent forms of prostate cancer.

Lumakras led to tumor shrinkage in 36% of NSCLC patients with KRAS G12C mutations.

New targeted therapy shrank tumors in nearly a quarter of patients with bile duct cancer.

Rybrevant is the first treatment for people with advanced non-small-cell lung cancer whose tumors have EGFR exon 20 insertion mutations.

Checkpoint inhibitor doubled disease-free survival time after surgery.

The Pfizer-BioNTech vaccine was 100% effective in a study of adolescents; trials for younger children are now underway.

An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.

75% of people treated with a combination of immunotherapy, targeted therapy and chemotherapy saw their tumors shrink.

The GI Genius aids clinicians in detecting potential irregularities during colon cancer screening and surveillance.

Zynlonta led to complete remission in nearly a quarter of patients with large B-cell lymphoma.

New checkpoint inhibitor Jemperli is approved for cancers with deficient mismatch repair mechanism for fixing damaged DNA.

Opdivo plus chemotherapy led to a significant improvement in overall survival.

The antibody-drug conjugate shrank tumors in 28% of people with locally advanced or metastatic urothelial cancer.